MedTrace Logo

Triple Combination Therapy of Choroidal Neovascularization in AMD, a Cost Effect and Efficient Therapeutic Treatment

NCT02287298 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2016-04-06

No results posted yet for this study

Summary

We propose to undertake a retrospective review of approximately 200 patients with a diagnosis of exudative macular degeneration treated with triple combination therapy (Bevacizumab, Dexamethasone and Photo-dynamic therapy) during the years of 2006 to 2010 at The Retina Center and compare those results with an additional group of approximately 200 patients also treated with triple combination therapy and 20 mg of daily oral zeaxanthin.

Conditions

  • Exudative Macular Degeneration

Interventions

PROCEDURE

TRIPLE COMBINATION THERAPY

TREATMENT WITH BEVACIZUMAB, DEXAMETHASONE AND PHOTODYNAMIC THERAPY

Sponsors & Collaborators

  • The Retina Center of St. Louis County, PC

    lead OTHER

Principal Investigators

  • ROBERT J OLK, MD · THE RETINA CENTER

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02287298 on ClinicalTrials.gov